Niere - AN 36/15 - CheckMate 214 Keine aktuellen Patienten und Klinikzahlen zu dieser
Studie.
Titel der Studie
CheckMate 214 - A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214, CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 214)